Two medicines, side by side
Cefixime vs doxycycline
Cefixime and doxycycline are both labeled for bacterial infections and urinary tract infections. Drugs@FDA records approvals of cefixime since 1989 and of doxycycline since 1967. Pharmacies paid $10.03 per cefixime 400 mg capsule and $0.118 per doxycycline hyclate 100 mg tablet (NADAC, October 7, 2026); the strengths differ, so the two prices are not like for like. Doxycycline's other strengths are brand-only: $18.18 per Doryx mpc DR 60 mg tablet. In FDA's classes, cefixime is a cephalosporin antibacterial and doxycycline a tetracycline-class drug.
Check it at the source: the cefixime FDA label on DailyMed (effective August 5, 2026); the doxycycline FDA label on DailyMed (effective July 25, 2025).
Highlights of the cefixime record
Cefixime (Suprax) · label of August 5, 2026
Used for
From the label: indicationsCefixime is a cephalosporin antibacterial drug indicated in the treatment of adults and pediatric patients six months and older with the following infections: Uncomplicated Urinary Tract Infections ( 1.1 ) Otitis Media ( 1.2 ) Pharyngitis and Tonsillitis ( 1.3 ) Acute Exacerbations of Chronic Bronchitis ( 1.4 ) Uncomplicated Gonorrhea (cervical/urethral) ( 1.5 ) Usage to Reduce Development of Drug-Resistant Bacteria […]
On the market
- Earliest approval on file
- April 28, 1989
- Generic labelers
- 6 labelers
- Pharmacy cost
- $10.03 per capsule
Supply and safety
- Shortage
- No current entry
- Recalls
- 8
Highlights of the doxycycline record
Doxycycline (Vibramycin) · label of July 25, 2025
Used for
From the label: indicationsTo reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline capsules and other antibacterial drugs, doxycycline capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. […]
On the market
- Earliest approval on file
- December 5, 1967
- Generic labelers
- 83 labelers
- Pharmacy cost
- $0.118 per tablet
Supply and safety
- Shortage
- A presentation being discontinued
- Recalls
- 19
Source: FDA drug labels via openFDA (Cefixime label of August 5, 2026, Doxycycline label of July 25, 2025); NDC Directory, Drugs@FDA, NADAC, FDA shortages and recalls (October 8, 2026)
How do cefixime and doxycycline differ on the record?
In FDA's classes, cefixime is a cephalosporin antibacterial and doxycycline a tetracycline-class drug.
Half-life, in each label's words: Cefixime, “The serum half-life of cefixime in healthy subjects is independent of dosage form and averages 3 to 4 hours but may …”; Doxycycline, “1.62 0.95 0.37 0.15 (μg/mL) Average Observed Values Maximum Concentration 3.61 μg/mL (± 0.9 sd) Time of Maximum …”
Generics: cefixime since 2004; doxycycline since 1973 (Drugs@FDA).
| Cefixime | Doxycycline | |
|---|---|---|
| Labeled for | Bacterial infections, Urinary tract infections | Urinary tract infections, Bacterial infections, Acne |
| Pharmacologic class | Cephalosporin Antibacterial | Tetracycline-class Drug |
| How it works (label) | Cefixime is a semisynthetic cephalosporin antibacterial drug [see Microbiology ( 12.4 )]. | n/a |
| Half-life (label) | The serum half-life of cefixime in healthy subjects is independent of dosage form and averages 3 to 4 hours but may range up to 9 hours in some normal volunteers. | 1.62 0.95 0.37 0.15 (μg/mL) Average Observed Values Maximum Concentration 3.61 μg/mL (± 0.9 sd) Time of Maximum Concentration 2.60 hr (± 1.10 sd) Elimination Rate Constant 0.049 per hr (± 0.030 sd) Half-Life 16.33 hr (± … |
| Earliest approval on file (Drugs@FDA) | April 28, 1989 | December 5, 1967 |
| First generic approved | February 12, 2004 | June 18, 1973 |
| Generic labelers (NDC) | 6 labelers | 83 labelers |
| Pharmacy cost (NADAC, each one's most listed form; strengths differ) | $10.03 per capsule (Cefixime 400 mg capsule) | $0.118 per tablet (Doxycycline hyclate 100 mg tablet) |
| 12-month price change | -0.6% | -2% |
| Boxed warning | No | No |
| Shortage now | No current entry | A presentation being discontinued |
| Recalls recorded | 8 | 19 |
| FAERS reports (a report is not proof of cause; counts follow how widely a medicine is used) | 2,959 | 69,571 |
| DEA schedule | none | none |
Source: Drugs@FDA, FDA NDC Directory, CMS NADAC of October 7, 2026, FDA shortages and recalls, FAERS via openFDA (FDA files October 8, 2026)
What next?
- Alternatives to cefixime
- every medicine labeled for the same conditions